文献速递临床试验与 GCP基础与转化研究

CD19 CAR-T细胞疗法联合预防性阿那白滞素治疗复发或难治性淋巴瘤:2期试验中期结果

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.
PubMed 文献 · Nat Med · 2023-07-03

这项2期试验在31例接受商业CD19 CAR-T治疗的复发/难治性大B细胞淋巴瘤和套细胞淋巴瘤患者中,从CAR-T输注后第2天至至少第10天皮下给予阿那白滞素。任何级别ICANS发生率为19%,严重(≥3级)ICANS为9.7%,无4级或5级ICANS;任何级别CRS为74%,严重CRS为6.4%;总体缓解率为77%,完全缓解率为65%。

要点

  • 31例可评估患者中,任何级别ICANS发生率19%,严重ICANS发生率9.7%。
  • 任何级别CRS发生率74%,严重CRS发生率6.4%。
  • 总体疾病缓解率77%,完全缓解率65%。

核心结论

  • 这些初步结果显示,预防性阿那白滞素使接受抗CD19 CAR-T细胞治疗的淋巴瘤患者ICANS发生率较低,并支持进一步研究阿那白滞素用于免疫相关神经毒性综合征。

研究设计与样本

  • 2期临床试验,报告队列1的非预设中期分析最终结果,患者从CAR-T输注后第2天至至少第10天皮下接受阿那白滞素。
  • 研究人群为接受商业抗CD19 CAR-T细胞治疗的复发/难治性大B细胞淋巴瘤和套细胞淋巴瘤患者,共31例接受治疗。
  • 主要终点为严重(≥3级)ICANS发生率;关键次要终点包括任何级别CRS和ICANS发生率以及总体疾病缓解。

主要发现

  • 31例接受治疗患者中,74%接受阿基仑赛,13%接受brexucabtagene autoleucel,4%接受替沙仑赛。
  • 任何级别ICANS发生于19%的患者,严重ICANS发生于9.7%的患者,无4级或5级ICANS事件。
  • 任何级别CRS发生于74%的患者,严重CRS发生于6.4%的患者。
  • 总体疾病缓解率为77%,完全缓解率为65%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In preclinical models, anakinra, an IL-1 receptor antagonist (IL-1Ra), reduced immune effector cell-associated neurotoxicity syndrome (ICANS) without compromising anti-CD19 chimeric antigen receptor (CAR) T-cell efficacy. We initiated a phase 2 clinical trial of anakinra in patients with relapsed/refractory large B-cell lymphoma and mantle cell lymphoma treated with commercial anti-CD19 CAR T-cell therapy. Here we report a non-prespecified interim analysis reporting the final results from cohort 1 in which patients received subcutaneous anakinra from day 2 until at least day 10 post-CAR T-cell infusion. The primary endpoint was the rate of severe (grade ≥3) ICANS. Key secondary endpoints included the rates of all-grade cytokine release syndrome (CRS) and ICANS and overall disease response. Among 31 treated patients, 74% received axicabtagene ciloleucel, 13% received brexucabtagene ciloleucel and 4% received tisagenlecleucel. All-grade ICANS occurred in 19%, and severe ICANS occurred in 9.7% of patients. There were no grade 4 or 5 ICANS events. All-grade CRS occurred in 74%, and severe CRS occurred in 6.4% of patients. The overall disease response rate was 77% with 65% complete response rate. These initial results show that prophylactic anakinra resulted in a low incidence of ICANS in patients with lymphoma receiving anti-CD19 CAR T-cell therapy and support further study of anakinra in immune-related neurotoxicity syndromes.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Park JH, Nath K, Devlin SM, et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023. PMID: 37400640. doi:10.1038/s41591-023-02404-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。